 JERUSALEM, Nov. 18, 2019 PRNewswire -- BiondVax Pharmaceuticals Ltd. BVXV announced today that enrollment and randomization of 12,463 participants in the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal influenza vaccine candidate is complete. BiondVaxs M-001 universal flu vaccine candidate is designed as a common denominator to influenza A and B viruses. Results from six completed human clinical trials indicate that M001 is safe, well-tolerated, and induces an immune response to a broad range of influenza strains. 